Tag : MEASURABLE RESIDUAL DISEASE

CONFERENCE UPDATE

Ponatinib + blinatumomab vs. imatinib + chemotherapy in newly diagnosed adult Ph+ ALL: First results from the GIMEMA ALL2820
The GIMEMA ALL2820 trial evaluated a chemo-free strategy with ponatinib + blinatumomab vs. imatinib + chemotherapy in adults with newly diagnosed Ph+ ALL. The initial results show that the experimental arm achieved higher complete hematologic response (CHR) and minimal residual disease (MRD) negativity, along with improved event-free survival and overall survival, and a manageable safety profile.